Year-over-year earnings per share growth for the last twelve months: Lucid Diagnostics Inc. (LUCD)
The growth of EsoGuard commercial tests and Medicare support are driving the development of Lucid Diagnostics Inc. (LUCD), as illustrated by the quarterly change in EPS. However, the -0.80 level reflects the state of the parameter amid slow physician adoption of diagnostics and regulatory barriers. Marketing expenses and challenges with procedure reimbursements are creating additional pressure on capital.
Analytical breakdowns and data insights for company Lucid Diagnostics, Inc (LUCD)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- book capitalization data:
- debt level and financial liquidity data:
Total Debt to Capital Lucid Diagnostics Inc.|LUCD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Lucid Diagnostics Inc.|LUCD - Company Total Debt Obligations|Debts to Book Capitalization Lucid Diagnostics Inc|LUCD - Company Long-Term Indebtedness|Company Current Liabilities Lucid Diagnostics|Quick Ratio luciddx.com
- earnings and market multiples details:
LUCD - Company Profit|Projected Future Earnings Lucid Diagnostics Inc.|LUCD - Business Payback Period|Forward P/E Multiple Lucid Diagnostics Inc|LUCD - PEG Multiple|EV/EBITDA Multiple Lucid Diagnostics Inc|LUCD - Operating profit before depreciation charges|Earnings per share for the last twelve months Lucid Diagnostics|LUCD - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months luciddx.com|LUCD - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Lucid Diagnostics Inc.
Analysis of all company metrics:Lucid Diagnostics - LUCD
Lucid Diagnostics Inc. (LUCD) expansion into the early diagnosis of precancerous conditions is driving the trajectory of quarterly EPS growth. This metric captures the change in net income per share over the reporting period, with calculations based on a comparison of current financial results against the same quarter of the previous year. The increase in this indicator confirms the effective monetization of gastroenterologists' demand for rapid tests. This positive trend signals strengthening capitalization and expanding business margins.
Key competitors
A: Quarterly EPS earnings growth|DGX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Illumina Corp|Exact Sciences Inc. (EXAS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Revvity, Inc. (RVTY)|Year-over-year earnings per share growth for the last twelve months BIO (bio-rad.com)|Anbio - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Sotera Health Corp SHC|QuidelOrtho Corp - Quarterly EPS earnings growth|OPKO Health Corp. (OPK) - Year-over-year net earnings per share growth for the last 12 months|CDNA: Quarterly EPS earnings growth|MRVI - Year-over-year net earnings per share change for the last twelve months|FLGT (Fulgent Genetics) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months LAB (Standard BioTools Inc)|Year-over-year net earnings per share growth for the last 12 months CTKB (Cytek Bio)|OSUR (OraSure Corp) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth XGN (Exagen)|MDXH: Year-over-year earnings per share growth for the last 12 months|Prenetics Global Ltd - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Insight Molecular Diagnostics IMDX|TRIB: Quarterly EPS earnings growth|ProPhase Labs Corp (PRPH) - Quarterly EPS earnings growth|AIMD (Ainos, Inc.) - Quarterly EPS earnings growth|CODX - Net earnings per share growth for the trailing year|Year-over-year earnings per share growth for the last twelve months HeartSciences (HSCS)|Biomerica Inc. - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cardio Diagnostics Holdings CDIO|Onconetix Corporation (ONCO) - Earnings per share growth in annualized terms for the last twelve months|VRAX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months bluejaydx.com BJDX|AWH (Aspira Women's Health Inc.) - Year-over-year net earnings per share growth for the last 12 months|AXDX: Year-over-year earnings per share growth rate for the last twelve months|CNTG (CENTOGENE) - Quarterly EPS earnings growth|Enzo (ENZ) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth FRES|Year-over-year net earnings per share growth for the last 12 months gtglabs.com GENE|Year-over-year earnings per share growth for the last twelve months 23andMe ME|Year-over-year net earnings per share change for the last twelve months Psychemedics Corp. (PMD)
